Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000040586
- Lead Sponsor
- Kyushu Study group of Clinical Cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 501
Inclusion Criteria
Not provided
Exclusion Criteria
1)Prior treatment with regorafenib or FTD/TPI 2)Patients with active multiple cancers 3)Patients who have symptomatic brain metastases. 4)Patients with diabetes mellitus, hyper tension, angina unstable, or symptomatic congestive heart failure (NYHA III/IV) that cannot be controlled adequately with medication. 5)Patients whom a lead investigator or primary physician deems are not appropriate for this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival (OS) of sequential treatment with regorafenib-FTD/TPI
- Secondary Outcome Measures
Name Time Method